In The News
Class action against Phoslock, KPMG should not wait for competing case, court told
Pacific Werribee shopping centre owners get preliminary trial in $200M defects dispute
Albanese government dumps misinformation bill
Katy Perry wins appeal in trade mark fight with Aussie designer
Lawyers in NSW can’t use AI to generate affidavits, witness statements, court says
Group members get nothing in RoundUp class action settlement
Second judge has rosier view of claims in class action over $85M development
Pharmacor says AstraZeneca’s Brilinta patent should not have been extended
Law firm report clears WiseTech founder Richard White of misconduct
Union boss says she faces charges over alleged $2.7M scheme, wants FWC case stayed
Please login to bookmarkClose

The High Court has rejected a bid by biopharmaceutical company Samsung Bioepis Australia to challenge a ruling granting Pfizer preliminary discovery for a potential patent infringement case over autoimmune drug Enbrel.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au